Guggenheim analyst Debjit Chattopadhyay raised the firm’s price target on Pharvaris (PHVS) to $39 from $32 and keeps a Buy rating on the shares after the company shared that its RAPIDe-3 trial hit on the primary and all 11 secondary endpoints. Post the RAPIDe-3 topline data readout, the firm is increasing its global peak sales estimate for deucrictibant to $1.65B from $1.4B during 2037.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PHVS:
- Pharvaris’s Deucrictibant: Promising Efficacy Amidst Uncertain Market Prospects
- Pharvaris price target raised to $30 from $27 at BofA
- Pharvaris price target raised to $41 from $37 at Morgan Stanley
- Pharvaris’ Deucrictibant Shows Promising Efficacy and Safety in RAPIDe-3 Study, Analyst Sets Buy Rating with Increased Price Target
- Pharvaris price target raised to $38 from $28 at Leerink